MPS Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
MPSLTD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 9.1 pts more than Nifty Microcap 250 and 7.6 pts more than its Printing & Publication peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
MPS Limited reported standalone total income of INR 38,125 lakhs for FY 2026 (up 14.4% from INR 33,336 lakhs), with profit after tax of INR 12,726 lakhs (up 15.7% from INR 11,000 lakhs). Earnings per share stood at INR 64.86. The Board declined to recommend a final dividend for FY 2025-26, citing cash deployment towards the acquisition of Unbound Medicine, Inc., completed on 9 February 2026. Walker Chandiok & Co LLP issued an unmodified (clean) audit opinion on both standalone and consolidated results. KPMG was appointed as new Internal Auditors for three years from FY 2026-27, replacing the existing firm. The statutory auditor (Walker Chandiok) was reappointed for a second five-year term. A scheme of amalgamation for ADI BPO Services Limited merging into MPS Limited is pending before NCLT. The company also recognized INR 611 lakhs impact from new labour codes (gratuity and compensated absences).
Strong profitability growth with clean audit signals financial health, though no dividend may disappoint income-focused investors. The Unbound Medicine acquisition and internal audit upgrade indicate strategic investment in future growth.